Prelude Capital Management, LLC Merus N.V. Transaction History

Prelude Capital Management, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$39.81 - $60.2 $374,214 - $565,880	9,400 New	9,400 $556,000
Q4 2020 Feb 16, 2021	SELL	$11.4 - $18.36 $100,320 - $161,568	-8,800 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$10.5 - $17.36 $92,400 - $152,768	8,800 New	8,800 $142,000
Q1 2020 May 15, 2020	SELL	$11.34 - $19.44 $2,608 - $4,471	-230 Closed	0 $0
Q4 2019 Feb 14, 2020	SELL	$14.08 - $18.5 $1,323 - $1,739	-94 Reduced 29.01%	230 $3,000
Q3 2019 Nov 14, 2019	SELL	$14.55 - $20.52 $567 - $800	-39 Reduced 10.74%	324 $6,000
Q2 2019 Aug 14, 2019	SELL	$12.93 - $16.83 $193 - $252	-15 Reduced 3.97%	363 $5,000
Q1 2019 May 15, 2019	BUY	$11.09 - $15.83 $288 - $411	26 Added 7.39%	378 $6,000
Q3 2018 Nov 14, 2018	BUY	$18.47 - $26.39 $6,501 - $9,289	352 New	352 $7,000

200

61.9M

243K

300K

Ticker MRUS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,878,200
Market Cap $1.93B
Description
Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase...

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Prelude Capital Management, LLC with notifications on news.